A new report on the health of the Massachusetts biotech scene has painted a mixed picture of how drug developers are faring in the Bay State.
When it comes to fundraising, the readout is certainly positive. The $3.45 billion in venture capital funding raised in the first half of 2026 is up 25% year over year and marks the best start to a year since 2023, according to biotech trade group MassBio’s latest Industry Snapshot.
Cambridge and Boston made up the lion’s share of venture dollars—at 47% and 26%, respectively—with Watertown coming in third at 12%.
The report, published this morning, noted that the eight IPOs in the state in the first half of the year are the highest amount of public listings since 2021. Last year, the state out-licensed $10.9 billion worth of biotech innovation across 27 deals, the report’s authors noted.
“This report shows the biotech flywheel is spinning once again,” MassBio CEO Kendalle Burlin O'Connell said in a release. “Capital is flowing, companies with compelling data are going public, and science is getting rewarded.”
Meanwhile, Massachusetts secured 9.3% of all National Institutes of Health (NIH) funding and led the nation with $477 in NIH funds per capita.
However, the authors noted that the total amount of funding had slipped, while the amount of awards fell 6.2%, which they described as “an early signal of shifting federal priorities that, if sustained, threaten the research base that feeds the whole ecosystem.”
Early funding was another area of potential concern. While the number of seed rounds for Massachusetts companies rose from 15 to 21 in the first half of the year, the average amount of these fundraises fell to $4.6 million from $7.6 million—a nearly 40% drop.
“If we’re not investing in early-stage biotechs, are we going to still be having the same successes five or 10 years from now?” MassBio’s Head of External Affairs Ben Bradford questioned in an interview with Fierce.
“We need to be making sure that we’re investing in that fundamental research stage,” Bradford added. “My hope is that with these exits that we’re seeing, some of that capital will be going back to early-stage companies. But until we see it, that’s a hope.”
There was a slight uptick in the proportion of NIH-awarded Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) grants, which rose to 10.6%, while the proportion of grant dollars rose to 11.3% last year.
The report's authors described these grants as a “lifeline for small biotechs working to hit milestones and generate data.” They hailed Congress' five-year reauthorization of these programs in April as a “critical victory and a meaningful step toward defending American competitiveness in early-stage innovation.”
However, the employment figures painted a more worrying picture, with biopharma R&D jobs in the state shrinking by around 3,600 roles over the course of 2025—equivalent to a 3.1% reduction. This marked the first annual decline in more than two decades, the report’s authors pointed out.
Bradford added some nuance to these figures, noting that much of the losses were contained in the first three quarters of last year. In fact, the state added 100 R&D jobs from October through December of 2025, he said.
“My hope is that with this re-infusion of capital in 2026, that the number will be going back up,” Bradford told Fierce.
Massachusetts continues to account for a disproportionate percentage of the U.S. biopharma market. Biopharmas across the state received 25% of the country’s VC funding in the first half of 2026, up from 22.5% last year. Its eight IPOs accounted for nearly two-thirds of the 13 American biopharmas that went public over those six months.
“As goes Massachusetts, goes the U.S. biopharma ecosystem,” Bradford told Fierce.
More than a fifth of the country’s biopharma workforce hails from the state, despite Massachusetts accounting for just 2% of the U.S. population.
Massachusetts-headquartered biopharmas make up 17% of the U.S. drug development pipeline and 6.2% of the global pipeline, according to the report. Pipeline growth in the state outpaced the country at 9.2%, compared to 0.6% for the U.S. as a whole.
But Boston's role as a source of biopharma innovation is increasingly viewed as in competition with China. With biotech growing as a geopolitical issue and federal legislators introducing bills to scrutinize biotech investments in China, Bradford suggested that any policy changes need to be balanced with domestic investment.
“Walling off China can't be the only approach,” Bradford said. “If we're going to restrict investment with China, it has to be done simultaneously with an incentives package to make sure that the U.S. remains competitive.”
Massachusetts certainly has the space available to enable a comeback. The amount of lab and manufacturing inventory almost tripled from 21.5 million square feet back in 2015 to 63.2 million square feet a decade later. This glut of floorspace has seen the vacancy rate rise to 31% across the state as of mid-2026.
But the amount of vacant lab space and slightly shrinking workforce could become an advantage, Bradford suggested.
“Massachusetts is in a unique position that we haven't been in in a long time,” he explained. “We have an opportunity as the industry is turning around for Massachusetts to be aggressive, because we have space for companies to move into, and we have high-quality talent sitting on the sidelines.”